Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.33 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.32 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.31 |
| ▸ | AURKA | O14965 | 2/20 | 0.31 |
| ▸ | TEK | Q02763 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 2/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | LYN | P07948 | 1/20 | 0.30 |
| ▸ | FGR | P09769 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326998 | 0.89 | GHSR (0.31) | MET | |
| SCHEMBL23326813 | 0.79 | MET (0.36) | METKDRLCK | |
| SCHEMBL23326809 | 0.77 | MET (0.33) | METKDRLCK | |
| SCHEMBL23326995 | 0.76 | MET (0.34) | MET | |
| SCHEMBL23326690 | 0.74 | HRH3 (0.37) | MET | |
| SCHEMBL23327025 | 0.71 | MET (0.32) | MET | |
| SCHEMBL23326983 | 0.70 | PTGDR2 (0.42) | — | |
| SCHEMBL23327015 | 0.69 | HDAC8 (0.38) | — | |
| SCHEMBL21470757 | 0.68 | MET (0.32) | MET | |
| SCHEMBL23326759 | 0.68 | MET (0.31) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | MET 1391/4885CAMKK1 8/4885CAMKK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.